FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for Generalized Myasthenia Gravis
Rapid Read

FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for Generalized Myasthenia Gravis

What's Happening? The U.S. Food and Drug Administration (FDA) has approved gefurulimab (Klygefa) as the first once-weekly, self-administered C5 inhibitor for adults with generalized myasthenia gravis (gMG). This approval, also granted in the EU and Japan, marks a significant advancement in the treat
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.